Pacific BioLabs would like to reassure its clients that we are continuing core operations at the moment and continue to support them in the development of their medical devices and […]

On 21 January 2020, Pacific BioLabs received unconditional approval for continuance of our ISO 17025:2017 accreditation, General Requirements for the Competence of Testing and Calibration Laboratories, as a result of […]

PBL clients are at the forefront of identifying new targets for drug discovery and development. Ophirex, a San Francisco Bay Area startup company founded by Matthew Lewin, M.D., Ph.D, is […]

Pacific BioLabs has purchased a new Sciex Triple Quad 6500+ LC-MS/MS. This instrument is a great addition to our existing AB Sciex API 4000 QTrap LC-MS/MS and Sciex 5600 Triple […]

The United States Pharmacopeia (USP) has published a new general chapter, the USP <60> which will become official on December 1, 2019. The chapter specifies tests to determine the presence […]

Fourier-transformed infrared spectroscopy, also known as FTIR, is a method of analyzing both organic and inorganic materials, and can provide a breakdown of their molecular makeup. Using FTIR, one can analyze […]

As you may be aware from our previous blog post, the European Union published the new Medical Device Regulation (MDR) on May 5th, 2017 and it is expected to be […]

Pacific BioLabs is proud to announce successful accreditation for ISO 17025:2017, General Requirements for the Competence of Testing and Calibration Laboratories, through the ANSI-ASQ National Accreditation Board.  PBL’s accreditation for […]

For their March issue, Medical Product Outsourcing Magazine interviewed Ryan Harper, PBL's Business Development Director, regarding recent medical device testing changes and developments.  The article discusses current industry trends, additions […]

The FDA recently launched a new pilot program called Quality in 510(k) or Quik that allows manufacturers of moderate risk medical devices to use the eSubmitter software program to submit […]